Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111317 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
A Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP015K, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02111317 is a Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP015K that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 24 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02111317, a Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP015K, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.
Conditions Studied
Interventions
- DRUG verapamil
- DRUG ASP015K
Study Locations (1)
California
- PAREXEL - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111317
The ClinicalTrials.gov registry entry for NCT02111317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which verapamil is the first listed.
NCT02111317 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02111317 about?
NCT02111317 is a clinical study titled "A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects". The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.
What is the current status of trial NCT02111317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2013-11.
What conditions does trial NCT02111317 study?
This clinical trial studies the following conditions: Healthy Subjects, Pharmacokinetics of ASP015K.
What interventions are being tested in trial NCT02111317?
The interventions under investigation include: verapamil (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT02111317?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02111317 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.